Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV:
LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech
company that leverages advancements in science and technology to
build breakthrough companies that transform human wellness, today
reported its financial results for the three months ended August
31, 2023 (“Q3 2023”) compared to the same period last year (“Q3
2022”). All financial figures are in Canadian dollars unless
otherwise indicated.
Third Quarter
- Net revenue of
$4.8 million in Q3 2023 compared to $6.8 million in Q3 2022.
- The strategic
focus on high margin activities and operational efficiency
continues to pay off with gross margins improving to 30% in Q3 2023
compared to 20% in Q3 2022.
- Gross profit
before inventory adjustment increased slightly to $1.4
million.
- Operating costs
and professional fees drop 21.4% to $3.1 million in Q3 2023
compared to $3.8 million in Q3 2022.
"Our steadfast commitment to transforming
Lifeist into a diversified wellness company with high-margin
business units remains on track," said Meni Morim, CEO of Lifeist.
"Our third-quarter performance, while presenting unique challenges,
underscores our unwavering dedication to continuous improvement and
efficiency. We have shifted our primary focus to gross profit
enhancement, rather than simply revenue growth, and together with
cost efficiency measures in Q3 2023, such actions yielded promising
results. With this strategic shift in focus, we will be better
positioned to weather industry fluctuations, foster profitability,
and deliver sustainable growth. We look forward to communicating
our progress within our business units as we continue to navigate
the challenging path forward."
Financial Summary
Net revenue was $4.8 million in Q3 2023 compared
to $6.8 million in Q3 2022 due to supply chain challenges impacting
CannMart’s cannabis revenue in Q3 2023, as compared to Q3 2022.
Gross profit before inventory adjustment
increased 2.9% to $1.4 million in Q3 2023 versus the same period
last year, with margins expanding to 30% in Q3 2023 from 20% in Q2
2023. The increase in margins in Q3 2023 as compared to Q3 2022
reflects the success of the Company’s strategic focus on individual
segments, geographies, and products, as well as a continuous effort
to improve production efficiencies across all segments.
Adjusted EBITDA loss increased to $2.1 million
in Q3 2023 compared to $1.2 million in Q3 2022 and net loss from
continuing operations was $2.4 million, or ($0.005) per diluted
share, in Q3 2023 compared to a loss of $1.9 million, or ($0.005)
per share, in Q3 2022. The increase in both adjusted EBITDA loss
and net loss was due largely to a significant one-time gain
recorded in Q3 2022 relating to the termination of a distribution
agreement. Excluding this one-time gain adjusted EBITDA and net
loss improved year over year.
Balance Sheet and Cash Flow
Cash and cash equivalents were $1.4 million at
August 31, 2023, compared to $3.8 million at November 30, 2022.
Inventories were $5.6 million at August 31, 2023
compared to $4.5 million at November 30, 2022.
The working capital position was $3.7 million at
August 31, 2023.
Net cash used by operations was $1.5 million in
Q3 2023 compared to $3.2 million in Q3 2022, due in part to lower
revenue from CannMart and reductions in overall operating
costs.
Additional Information
The Company’s complete financial statements and
management’s discussion & analysis (“MD&A”) for Q3 2023 are
available on Lifeist’s website (www.lifeist.com) and SEDAR+
(www.sedarplus.ca).
About Lifeist Wellness Inc.
Sitting at the forefront of the post-pandemic
wellness revolution, Lifeist leverages advancements in science and
technology to build breakthrough companies that transform human
wellness. Portfolio business units include: CannMart, which
operates a B2B wholesale distribution business facilitating
recreational cannabis sales to Canadian provincial government
control boards; CannMart Labs, a BHO extraction facility for the
production of high margin cannabis 2.0 products; Aus Vapes,
Australia’s largest online retailer of vaporizers and accessories;
and Mikra, a biosciences and consumer wellness company seeking to
develop innovative therapies for cellular health.
Information on Lifeist and its businesses can be
accessed through the links below:
www.lifeist.comwww.cannmart.comwww.australianvaporizers.com.auwww.wearemikra.com
ContactsMeni Morim, CEO Lifeist
Wellness Inc.Tel: 647-362-0390Email: ir@lifeist.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release or has in any way approved
or disapproved of the contents of this press release.
Non-IFRS Financial Measures
Management evaluates the Company’s performance
using a variety of measures, including “Net loss before income tax,
depreciation and amortization” and “Adjusted EBITDA”. The non-IFRS
measures discussed below should not be considered as an alternative
to or to be more meaningful than revenue or net loss. These
measures do not have a standardized meaning prescribed by IFRS and
therefore they may not be comparable to similarly titled measures
presented by other publicly traded companies and should not be
construed as an alternative to other financial measures determined
in accordance with IFRS.
The Company believes these non-IFRS financial
measures provide useful information to both management and
investors in measuring the financial performance and financial
condition of the Company.
Management uses these and other non-IFRS
financial measures to exclude the impact of certain expenses and
income that must be recognized under IFRS when analyzing
consolidated underlying operating performance, as the excluded
items are not necessarily reflective of the Company’s underlying
operating performance and make comparisons of underlying financial
performance between periods difficult. From time to time, the
Company may exclude additional items if it believes doing so would
result in a more effective analysis of underlying operating
performance. The exclusion of certain items does not imply that
they are non-recurring.
(i) Current and deferred income taxes,
depreciation and amortization, and share-based compensation were
excluded from the Adjusted EBITDA calculation as they do not
represent cash expenditures.(ii) Other income consisting of gain on
disposal of subsidiary, interest income, realized gain on
disposition of AFS investments, unrealized gain on derivatives and
other miscellaneous non-recurring income were excluded from
Adjusted EBITDA calculation.(iii) Non-recurring costs related to
restructuring and legacy issues were excluded from Adjusted EBITDA
calculation.(iv) Impairment loss relating to goodwill, customer
list, domains and brand names were excluded from Adjusted EBITDA
calculation.(v) Impairment loss relating to receivable is a
provision for expected credit loss to an associate and was excluded
from Adjusted EBITDA calculation.(vi) Share of associates loss, net
of tax, is excluded due to lack of control.
Forward Looking Information
This news release contains “forward-looking
information” within the meaning of applicable securities laws. All
statements contained herein that are not historical in nature
contain forward-looking information. Forward-looking information
can be identified by words or phrases such as “may”, “expect”,
“likely”, “should”, “would”, “plan”, “anticipate”, “intend”,
“potential”, “proposed”, “estimate”, “believe” or the negative of
these terms, or other similar words, expressions and grammatical
variations thereof, or statements that certain events or conditions
“may” or “will” happen.
The forward-looking information contained
herein, including, without limitation, statements related to: the
Company’s continuing focus and future actions to foster
profitability and deliver sustainable growth, and its expectations
from such actions to increase revenue growth and profitability are
made as of the date of this press release and is based on
assumptions management believed to be reasonable at the time such
statements were made, including, without limitation, Lifeist’s
ability to realize the anticipated benefits from focusing on gross
profit enhancement, the Company’s expectation that the
nutraceutical and wellness market will continue to develop as
currently anticipated, the nutraceutical market will continue to be
a multi-billion dollar high-margin market, the introduction of new
products and brands will generate additional revenue, expectations
that the Company’s current and future products will gain market
acceptance, as well as other considerations that are believed to be
appropriate in the circumstances. While we consider these
assumptions to be reasonable based on information currently
available to management, there is no assurance that such
expectations will prove to be correct. By its nature,
forward-looking information is subject to inherent risks and
uncertainties that may be general or specific and which give rise
to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. A variety of factors,
including known and unknown risks, many of which are beyond our
control, could cause actual results to differ materially from the
forward-looking information in this press release. Such factors
include, without limitation: the inability of the Company to
develop its business as anticipated and to increase revenues and/or
its profitable margin on such revenues, unanticipated changes to
current regulations that would adversely impact the Company’s
businesses, the unanticipated decline in demand for cannabis
products, competition from others, the risk that the expected
demand for nutraceutical products in general and those of Mikra in
particular does not develop as anticipated, regulatory risk, risks
relating to the Company’s ability to execute its business strategy
and the benefits realizable therefrom and risks specifically
related to the Company’s operations. Additional risk factors can
also be found in the Company’s current MD&A which has been
filed under the Company’s SEDAR+ profile at www.sedarplus.ca.
Readers are cautioned not to put undue reliance on forward-looking
information. The Company undertakes no obligation to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable law. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement.
Source: Lifeist Wellness Inc.
Lifeist Wellness (TSXV:LFST)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Lifeist Wellness (TSXV:LFST)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024